UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 6, 2023

SENTI BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)

Delaware	001-40440	86-2437900
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

2 Corporate Drive, First Floor
South San Francisco, California 94080
(Address of principal executive offices including zip code)

Registrant's telephone number, including area code: (650) 382-3281

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	**SNTI**	**The Nasdaq Global Market**

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 8.01 Other Events.

Beginning on January 9, 2023, Senti Biosciences, Inc. (the "Company") will participate in the 41st Annual J.P. Morgan Healthcare Conference with investors. A copy of the Company's presentation materials has been posted to the Company's website and is filed herewith as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.

Cautionary Statement

This filing and the exhibits include "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act, and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies, and prospects, which are based on the information currently available to us and on assumptions we have made. Important factors that may cause actual results to differ materially from those described in the forward-looking statements are disclosed in the respective exhibits and in the "Risk Factors" contained in the Company's Form 10-Q filed with the Securities and Exchange Commission (the "Commission") on November 10, 2022, and other filings we make with the Commission. All forward-looking statements are expressly qualified in their entirety by such factors. We do not undertake any duty to update any forward-looking statement except as required by law.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Corporate presentation.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SENTI BIOSCIENCES, INC.

Date: January 6, 2023

By: /s/ Timothy Lu
Name: Timothy Lu, M.D., Ph.D.
Title: Chief Executive Officer & President


SENTI BIO™
Corporate Presentation
January 2023
JANUARY 2023 | SENTI BIOSCIENCES

Disclaimer

Forward Looking Statements

This presentation contains forward-looking statements. Statements we make in this presentation may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are usually identified by the use of words such as "anticipates," "believes," "estimates," "expects," "future," "opportunity," "proposed," "targets," "intends," "may," "plans," "projects," "seeks," "should," "will," and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements, including statements relating to the attributes and benefits of our technology platform and our product candidates, including their therapeutic potential, our plans to submit INDs for our product candidates and the timing of such submissions, the generation and presentation of data regarding preclinical programs and the related timing, our proposed Phase 1 studies, including study design and endpoints, our ability to enter into new collaborations, our manufacturing process and its potential benefits, and our cash runway, reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Many actual events and circumstances are difficult or impossible to predict, are beyond our control and will differ from assumptions. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, the risk that results observed in studies of our product candidates, including preclinical studies and future clinical trials of any of our product candidates, will not be observed in ongoing or future studies involving these product candidates, the risk that we may cease or delay clinical development of any of our product candidates for a variety of reasons (including requirements that may be imposed by regulatory authorities on the initiation or conduct of clinical trials, the amount and type of data to be generated, or otherwise to support regulatory approval, difficulties or delays in subject enrollment and continuation in current and planned clinical trials, difficulties in manufacturing or supplying our product candidates for preclinical and clinical testing, and any adverse events or other negative results that may be observed during preclinical or clinical development), our ability to obtain, maintain and protect our intellectual property, our dependence on third parties for development and manufacture of product candidates, our ability to manage expenses and to obtain additional funding when needed to support our business activities and establish and maintain strategic business alliances and new business initiatives, the impacts of macroeconomic and geopolitical events, including changing conditions from the COVID-19 pandemic, the hostilities in Ukraine, increasing rates of inflation and rising interest rates on business operations and expectation, and the risk that our product candidates may not produce therapeutic benefits or may cause other unanticipated adverse effects, as well as those set forth in the section titled "Risk Factors" in our Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on November 10, 2022, and our subsequent SEC filings. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Trademarks

This document contains references to trademarks, trade names and service marks belonging to other entities. Solely for convenience, trademarks, trade names and service marks referred to in this presentation may appear without the ® or TM symbols, but such references are not intended to indicate, in any way, that the applicable owner will not assert, to the fullest extent under applicable law, its rights to these trademarks and trade names. We do not intend our use or display of other entities' trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other entities.

Pioneering Smarter Next Generation Cell and Gene Therapies

SENTI BIO

Gene Circuits

Multi-Arming
Logic Gating (OR and NOT GATEs)
Regulator Dial
Smart Sensor

to

reprogram cells to sense, compute, and respond to disease

Two INDs Anticipated in 2023

Pipeline of CAR-NK Cell Therapies

Diseases: blood cancers and solid tumors
Gene Circuit advantages: multi-arming, selectivity and control
Manufacturing: off-the-shelf, scalable with outpatient potential

Spark, BlueRock

Platform Collaborations

Precise gene therapy for eye, CNS and liver applications
Targeted and controllable iPSC cell therapies for regenerative medicine

Founded 2016 | Public June 2022 | Anticipated Cash Runway into 2024 | Headquartered South San Francisco, CA

CNS: Central Nervous System

Industry-Leading Management With Top-Tier Board and Scientific Advisors

Executive Team

Tim Lu, MD, PhD
CEO & Co-Founder

Philip Lee, PhD
CTO & Co-Founder

Deb Knobelman, PhD
CFO

Kanya Rajangam, MD, PhD
Chief Medical and Development Officer (CMDO)

Scientific Advisors

James Collins, PhD	Scientific Co-Founder, MIT
Michael Andreeff, MD, PhD	MD Anderson Cancer Center
Lawrence Fong, PhD	UCSF
Martin Fussenegger, PhD	ETH Zurich
Michael Kalos, PhD	Arsenal, Janssen, Lilly
Ahmad (Mo) Khalil, PhD	Boston University
Robin Taylor, PhD, MBA	SeaGen, Genentech
Michael Varney, PhD	Erasca, Genentech
Wilson Wong, PhD	Scientific Co-Founder, Boston University

Board of Directors

Susan Berland	Senior Financial Executive
Brenda Cooperstone, MD	Pfizer Rare Disease
Ed Mathers	NEA
James Collins, PhD	Scientific Co-Founder, MIT
Omid Farokhzad, MD	Seer Inc.
David R. Epstein	Seagen Inc.
Tim Lu MD, PhD	CEO & Co-Founder


CAR-NK Cell Therapy
Pipeline
JANUARY 2023 | SENTI BIOSCIENCES

Gene Circuits Designed to Solve for Key Cell Therapy Challenges

Cancer Cell Therapy Challenges	Senti's Gene Circuit Solutions	
Lack of NK cell expansion and persistence	Multi-Arming	Autocrine and paracrine activation with proprietary **Calibrated Release** IL-15 (crIL-15) and other complementary cytokines (e.g., IL-21)
Antigen escape and tumor heterogeneity	Logic Gating	Bivalent activating CAR with **OR Logic Gate**
Dirty targets (on-target, off-tumor toxicity)	Logic Gating	Inhibitory CAR protects healthy cells with **NOT Logic Gate**
Immunosuppressive tumor microenvironment	Regulator Dial	Pulsed Calibrated Release IL-12 with small molecule-controlled **Regulator Dial**

NK Cells Compare Favorably to T Cell Based Therapies

Capabilities	Current Auto T Cells	Senti's CAR-NK Cells
Off-the-shelf potential with broad patient accessibility	✗	✓
Designed with Logic Gates to achieve enhanced selectivity and safety	✗	✓
Engineered with enhanced persistence	N/A	✓
Engineered to stimulate the patient immune system	✗	✓

Extensive clinical experience with allogeneic donor-derived unengineered NK cells[1]

- ~70 global peripheral blood derived unengineered NK cell therapy clinical trials[1]
- Well-tolerated (~500 patients clinical experience)[2]
  - No (or minimal) CRS, neurotoxicity, GvHD
- Anti-tumor activity observed in AML[2]
  - 19% CR in 105 R/R AML patients aggregated from multiple trials

Key limitations of unengineered NK cells

Limited activity beyond AML, persistence, durability, donor variability and select single clinical center usage

Senti's Gene Circuit technology, donor selection and scalable manufacturing address these limitations

[1] Lamers-Kok Journal of Hematology & Oncology 2022; [2] Bachier 2021

Calibrated Release IL-15 (crIL-15) Increases Persistence and Activation of Both CAR-NK and Immune Cells in Tumor Milieu

crIL-15: IL-15 released by local proteases → autocrine and paracrine effects





Phospho STAT5 levels increased in T cells exposed to supernatant from either crIL-15 or sIL-15 CAR-NK cell culture

crIL-15 has paracrine activity and activates resting immune cells



crIL-15 increases persistence of CAR- NK cells



crIL-15 increases CAR-NK serial killing compared to secreted IL-15

sIL-15: secreted wild-type IL-15

Senti's Discovery Platform for Tumor-Associated Antigen and Protective Antigen to Generate Many Targets for New Logic Gated CAR-NK Candidates



Gene Circuits Can Vastly Expand the Universe of Cancer Targets and Tumors That Can Be Addressed With Cell Therapies



* Senti's current CAR-NK programs

Senti's Next Generation CAR-NK Cell Therapy Pipeline Tackles Hard to Treat Cancers

Program	Target	Indications	Discovery	IND enabling	Phase 1	Gene Circuits
SENTI-202	CD33 and/or FLT3	AML, MDS and other blood cancers		2H 2023 IND		✓ Multi-Arming: designed for enhanced efficacy ✓ crIL-15: autocrine and paracrine activation ✓ OR GATE: bivalent activation ✓ NOT GATE selectivity: healthy cell protection
SENTI-301A	GPC3	HCC and other solid tumors		2023 IND		✓ Multi-Arming: designed for enhanced efficacy ✓ crIL-15: autocrine and paracrine activation
SENTI-401	CEA	CRC and other solid tumors		2024 IND		✓ Multi-Arming: designed for enhanced efficacy ✓ crIL-15: autocrine and paracrine activation ✓ NOT GATE selectivity: healthy cell protection ✓ IL-21: sustained anti-tumor function
Additional Programs	Undisclosed	Other tumors				Program candidates integrate Multi-Arming, Logic Gating and/or Regulator Dial Gene Circuits


Manufacturing
JANUARY 2023 | SENTI BIOSCIENCES

Scalable Manufacturing to Support Off-The-Shelf CAR-NK Products



Senti Selects NK Cell Donors to Support Robust Cell Expansion



Senti screens and selects GMP donors using NK cell expansion and other functional attributes to minimize variability



Senti process can potentially generate over 100 trillion NK cells from a single donor collection

Senti's Cryopreservation Process Retains High Potency of CAR-NK Products Supporting Multi-Country and Multi-Site Clinical Evaluation



CAR-NK cell viability retained post-thaw in vitro



In vivo activity with cryopreserved CAR NK cells in MOLM13 AML NSG mouse model
(10 days after single dose)


Pipeline Products
JANUARY 2023 | SENTI BIOSCIENCES

SENTI-202 for CD33 and/or FLT3 Expressing Blood Cancers



LSCs: Leukemic Stem Cells

Multi-Armed, off-the-shelf, selective CAR-NK

- ***OR GATE:*** *bivalent* CD33 and/or FLT3 activation → potential for deep and durable responses in acute myeloid leukemia (AML) and other blood cancers.
- ***NOT GATE:*** inhibition by endomucin (EMCN) protective antigen selectively expressed on healthy hematopoietic stem cells (HSCs) → potential for improved safety and increased therapeutic window
- ***crIL-15*** → potential for increased persistence, autocrine and paracrine immune cell activation

On track for IND in 2H 2023

SENTI-202 Has Shown Robust Preclinical Activity Across Multiple AML / MDS Models



Broad in vitro killing of primary AML and MDS tumor cells



In vivo suppression of tumor and increased mouse survival in MV4-11 AML NSG mouse model

Group	Vehicle	Unengineered NK Cells	SENTI-202 CAR-NK Cells
Median Survival (Days)	*49*	*55*	*81.5*

SENTI-202 Preclinical Selectivity via Inhibitory CAR Binding Endomucin to Protect Healthy Primary Human HSCs

Endomucin was identified and validated by bioinformatics, flow cytometry, and functional assays, and is expressed on up to 76% of HSCs, but not on leukemic stem cells or blasts.



In vitro protection of healthy primary human HSC fraction expressing EMCN



In vivo protection of EMCN+ model healthy cells

Proposed Phase 1 Study in R/R CD33+ and/or FLT3+ Malignancies With Focus on AML

High unmet need in patients with AML

- 20,050 newly diagnosed AML patients in the US[1]
- 30.5% 5-year survival[1]

Proposed Phase 1 study anticipated to enroll R/R CD33+ and/or FLT3+ heme malignancies

- Modified "3+3" study design
- Received at least 1 prior treatment including targeted agents if FLT3, IDH1/2 mutation+
- 2 of 3 patients at each dose level with AML
- Disease specific expansion cohorts for AML and MDS

Planned study endpoints

- Safety, DLT, identify recommended Phase 2 dose
- Efficacy using standard ELN 2022 criteria for AML and other disease specific consensus criteria
- PK, pharmacodynamics including endomucin protection, immunogenicity

Planned Study Treatment/ Cycle

Planned data-driven seamless Phase 1 to pivotal design

[1] Seer estimates

SENTI-301A for GPC3 Expressing Solid Tumors



Multi-Armed, off-the-shelf, selective CAR-NK

- ***GPC3 activating CAR*** → hepatocellular carcinoma (HCC) and other solid tumors
- ***crIL-15*** → potential for increased persistence, autocrine and paracrine immune cell activation

On track for IND in 2023

SENTI-301A Aims to Address Unmet Needs in GPC3 Expressing Solid Tumors With a Focus on HCC

GPC3 is an attractive cancer target

- Glypican-3 (GPC3) is a membrane-bound protein normally expressed in fetal tissues such as liver and placenta.
- After birth, GPC3 is not expressed in healthy liver tissue or other human organs but is overexpressed in different tumor types, notably in HCC (70-90% GPC3+)[1] and other solid tumors (29-54%[2] GPC3+)
- Academic GPC3 CAR-T cell trials have shown promising activity but limited by CAR-T toxicities precluding multiple dosing and limited durability[3]

SENTI-301A is designed to target GPC3 expressing tumors

- Aim to address unmet need in HCC as the initial focus given the lack of targeted therapies and lack of effective immunotherapies
- Tackle multiple solid tumors with high GPC3 antigen expression via NKs multi-armed with GPC3 CAR and crIL-15



Common GPC3 expressing tumors

[1] Zheng 2022, [2] Moek 2018, [3] Shi 2020

SENTI-301A Preclinical Anti-Cancer Activity and Proposed Phase 1 Study in Advanced Solid Tumors With Focus on HCC

High unmet need in patients with liver cancer

- 41,260 newly diagnosed HCC patients in the US[1]
- 20.8% 5-year survival rate[1]

Proposed Phase 1 study anticipated to enroll an advanced metastatic GPC3 solid tumor population

- Must have received standard of care
- Advanced solid tumors with focus on HCC during dose finding
- Disease specific expansion cohorts of advanced HCC and other solid tumors including lung cancer

Planned study treatment

- Multi-dose and multi-cycle following conditioning
- 2-3 cell dose levels



Effective in vitro serial killing of HepG2 cell line



Increased survival and response in HepG2 mouse model

Group	Vehicle	Unengineered NK Cells	SENTI-301A CAR-NK Cells
Median Survival (Days)	*48*	*49.5*	*93.5*

[1] Seer estimates (liver and intrahepatic bile duct cancer combined)

SENTI-401 for CEA Expressing Solid Tumors



Multi-Armed, off-the-shelf, selective CAR-NK

- ***CEACAM5 (CEA) activating CAR*** → metastic colorectal cancer (mCRC) and other solid tumors
- ***NOT GATE:*** inhibition by VSIG2 antigen on healthy epithelial cells → potential for improved safety, increased therapeutic window and reduced on-target, off-tumor toxicity
- ***crIL-15*** → potential for increased persistence and autocrine and paracrine immune cell activation
- ***IL-21*** → construct to further potentiate persistence and efficacy of CAR-NK cells and to stimulate endogenous immune cells

SENTI-401 Aims to Address Unmet Needs in CEA Expressing Solid Tumors With a Focus on mCRC

High unmet need in patients with colorectal cancer

- 151,030 newly diagnosed CRC patients in the US[1]
- 65.1% 5-year survival rate[1]

CEA is an attractive cancer target

- CEA is overexpressed in several solid tumors, including CRC (~85-90% CEA+) as well as NSCLC, gastric and esophageal cancers
- CEA-targeted adoptive T cell trials reported objective regression but also observed colitis potentially from on-target, off-tumor toxicity[2]

SENTI-401 is designed to target CEA expressing tumors while minimizing on-target, off-tumor toxicity using a NOT GATE

Tumor Types With CEA Overexpression[3]



Healthy Tissues With CEA Overexpression[3]



[1] Seer estimates, [2] Parkhurst, et al. [3] Median expression of tumor and normal samples in body map (Log2 (TPM+1) scale). Source: TCGA, Gtex and Nat Genetics 2020 [GSE132465]

Robust Preclinical Activity With CEA CAR-NK Cells That Is Augmented by Multi-Arming With Both crIL-15 and IL-21



Arming CEA CARs with the combination of Senti's proprietary crIL-15 and IL-21 results in improved anti-tumor activity of NK cells

TGFβ is an immunosuppressive tumor factor highly expressed in CRC, known to suppress immune activation and help tumor escape[1]



Sustained serial killing with CEA CAR-NK cells expressing crIL-15 and IL-21 even in the presence of the immunosuppressive cytokine TGFβ

[1] Nature 2018

Senti's Approach to Select Paired Target and Protective Antigens Translates to Rapid Preclinical Proof of Principle for Protecting Healthy VSIG2+ cells

VSIG2 was identified by bioinformatics using single cell RNA sequencing and validated as protective antigen with immunohistochemistry



CEACAM5: 85-90% of CRC and 40-60% of other solid tumors including lung cancer[1]



Decreased cell killing of VSIG2 expressing cells with addition of inhibitory CAR construct

[1] Goldstein 2005

Senti's Regulator Dial Enables On-Demand Production of crIL-12 Controlled via Multiple Distinct FDA-Approved Small Molecule Oral Drugs



IL-12 is a well-known immuno-stimulatory cytokine

- Increases NK and T cell activation and inhibits immunosuppressive cells such as tumor-associated macrophages
- Responses noted with systemic administration of IL-12[1]

IL-12 clinical use has been limited by toxicities

- Regulator Dials control IL-12 production with FDA approved oral drugs such as grazoprevir (GRZ) and endoxifen (active metabolite of tamoxifen)
- Opportunities for application across multiple solid tumor indications

[1] Leonard 1997



Drug dose-dependent crIL-12 production



Dose-dependent, reversible crIL-12 controlled by GRZ in vivo



CAR-NK activity suppressed by M2 macrophages → Activity restored by GRZ induced crIL-12 via Regulator Dial


JANUARY 2023 | SENTI BIOSCIENCES
Platform and Collaboration Opportunities

Multiple Platform Collaborations Extend Utility of Gene Circuits

Program	Indications	Gene Circuit	Discovery	IND enabling	Phase 1	Rights
Gene Therapies for Tissue-Directed Targets						
GC-1001/GC-1002	Eye	Smart Sensor				Spark Therapeutics, Roche
GC-1003/GC-1004	CNS	Smart Sensor				
GC-1005	Liver	Smart Sensor				
Cell Therapies for Regenerative Medicine						
GC-1101	Regenerative Medicine	Regulator Dial				BlueRock Therapeutics, Bayer
GC-1102	Regenerative Medicine	Regulator Dial				
GC-1103	Regenerative Medicine	Smart Sensor				

Two Collaborations to Develop Next Generation Cell and Gene Therapies

Spark

Collaboration for gene therapies

AAV Gene Therapy with Cell Type-Specific Smart Sensor



Synthetic Promoter Performance Profile:



BlueRock THERAPEUTICS

Collaboration for cell therapies

Gene Circuit-Engineered "Smart" Regenerative Medicines

Smart Sensor Promoters Are Designed to Address Key Challenges in Gene Therapy

Gene Therapy Challenges	Senti's Gene Circuit Solutions
Off-target tissue toxicity	Smart Sensor → Enhance target tissue specificity and limit off-target tissue toxicity
Sub-optimal therapeutic performance	Smart Sensor → Improve expression and increase potency

Smart Sensor Promoters enable next-generation gene therapy by:

- Enhancing specificity to target tissue(s) (and thus limiting off-target tissue toxicities) and
- Increasing strength, potentially enabling more efficacious therapies

Smart Sensor Promoter Data



Senti's Gene Circuit Technology Has Broad Potential Across Modalities and Therapeutic Areas



2022 Milestones and Upcoming Value Driving Milestones

Program	2022 Completed Milestones	2023 Anticipated Milestones
SENTI-202 *CD33 and/or FLT3* *AML, MDS and other blood cancers*	Presented key preclinical data at ASH in December 2022	File IND application in 2H 2023
SENTI-301A *GPC3* *HCC and other solid tumors*	Presented preclinical data at SITC in November 2022	File IND application in 2023
SENTI-401 *CEA* *CRC and other solid tumors*	Presented preclinical data at SITC in November 2022	Present data at key scientific conferences
Additional Programs *Other tumors*	Initiated research work on additional CAR-NK pipeline programs	Pre-clinical PoCs for additional pipeline candidates
Manufacturing	Initiated manufacturing activities and presented data at key conferences	


SENTI BIO
Thank you
JANUARY 2023 | SENTI BIOSCIENCES